BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today reported that three abstracts related to the Phase 3 REPLACE study of Natpara™ in hypoparathyroidism will be presented at ENDO 2012, the annual meeting of The Endocrine Society in Houston, TX, June 23-26, 2012.
